Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 12/20 | 0.65 |
| ▸ | IL17A | Q16552 | 1/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.62 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.62 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.62 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.62 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.62 |
| ▸ | PARP1 | P09874 | 2/20 | 0.61 |
| ▸ | BRD1 | O95696 | 1/20 | 0.47 |
| ▸ | BRD2 | P25440 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL378069 | 0.85 | BRD4 (0.81) | BRD4IL17AHDAC1HDAC3HDAC4 | |
| Apabetalone SCHEMBL29352238 | 0.83 | BRD4 (0.84) | BRD4IL17AHDAC1HDAC3HDAC4 | |
| Apabetalone SCHEMBL145019 | 0.83 | BRD4 (0.84) | BRD4IL17AHDAC1HDAC3HDAC4 | |
| SCHEMBL378070 | 0.81 | BRD4 (0.72) | BRD4IL17AHDAC1HDAC3HDAC4 | |
| SCHEMBL377925 | 0.81 | BRD4 (0.77) | BRD4IL17AHDAC1HDAC3HDAC4 | |
| SCHEMBL30052937 | 0.81 | BRD4 (0.74) | BRD4IL17AHDAC1HDAC3HDAC4 | |
| SCHEMBL347354 | 0.81 | BRD4 (0.74) | BRD4IL17AHDAC1HDAC3HDAC4 | |
| SCHEMBL17930617 | 0.81 | BRD4 (0.74) | BRD4IL17AHDAC1HDAC3HDAC4 | |
| SCHEMBL30052713 | 0.81 | BRD4 (0.72) | BRD4IL17AHDAC1HDAC3HDAC4 | |
| SCHEMBL148581 | 0.81 | BRD4 (0.72) | BRD4IL17AHDAC1HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10131640-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2018-11-20 | — | — | US | claimed |
| US-20160137613-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2016-05-19 | — | — | US | claimed |
| WO-2013175281-A1 | USE OF SUBSTITUTED 2-PHENYL-3H-QUINAZOLIN-4-ONES AND ANALOGS FOR INHIBITING BROMODOMAIN AND EXTRA TERMINAL DOMAIN (BET) PROTEINS | RVX THERAPEUTICS INC. (CA) | 2013-11-28 | — | — | WO | claimed |
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | claimed |
| EP-2408454-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-01-25 | — | — | EP | claimed |
| WO-2010106436-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-09-23 | — | — | WO | claimed |
| EP-2408454-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2024-07-24 | — | — | EP | disclosed |
| US-11407719-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2022-08-09 | — | — | US | disclosed |
| US-20210070716-A1 | ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2021-03-11 | — | — | US | disclosed |
| US-20210070716-A1 | ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2021-03-11 | — | — | US | disclosed |
| US-10882828-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2021-01-05 | — | — | US | disclosed |
| US-10882828-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2021-01-05 | — | — | US | disclosed |
| US-20190119222-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2019-04-25 | — | — | US | disclosed |
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-02-16 | — | — | US | disclosed |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-02-16 | — | — | US | disclosed |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-02-16 | — | — | US | disclosed |
| EP-2408454-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010106436-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010106436-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407719-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | BRD4 744/4885IL17A 264/4885HDAC1 576/4885 |
| US-20160137613-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | BRD4 700/4885IL17A 226/4885HDAC1 582/4885 |
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | PHKB, BAZ2A, EP300 | BRD4 10/4885IL17A 4442/4885HDAC1 30/4885 |
| US-10882828-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | BRD4 744/4885IL17A 264/4885HDAC1 576/4885 |
| US-20210070716-A1 | ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | BRD4 744/4885IL17A 264/4885HDAC1 576/4885 |
| US-10131640-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | BRD4 744/4885IL17A 264/4885HDAC1 576/4885 |
| US-20190119222-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | BRD4 700/4885IL17A 226/4885HDAC1 582/4885 |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | BRD4 700/4885IL17A 226/4885HDAC1 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.